Everest Medicines (SEHK:1952) Stock Valuation After New Ophthalmology And Cardiovascular Licensing Deals

Recent deal activity at Everest Medicines (SEHK:1952), including the LNZ100 ophthalmology license in Greater China and the Sumecigrel cardiovascular collaboration, has put the stock back in focus for investors evaluating its business development approach.

See our latest analysis for Everest Medicines.

These licensing deals have arrived during a weak patch for the stock, with the share price down 26.91% year to date and the 1-year total shareholder return falling 45.09%. However, the 3-year total shareholder return is up 72.05%, suggesting longer term investors have seen very different outcomes from recent buyers.

If these partnerships have you thinking about where else growth stories could come from in healthcare, it may be worth scanning 133 healthcare AI stocks for your next idea.

With Everest Medicines trading at HK$27.70 and third party targets indicating a substantial gap to HK$47.05, along with an intrinsic value estimate at an even steeper discount, investors now face a key question: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 43.7% Undervalued

With Everest Medicines last closing at HK$27.70 against a narrative fair value estimate of HK$49.19, the current price sits well below that modeled outcome.

The company's robust and diversified pipeline spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies with multiple assets moving toward late-stage trials positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.

Read the complete narrative.

Curious what kind of revenue ramp, margin shift, and future earnings multiple need to line up for that HK$49.19 figure to make sense? The narrative leans on tight assumptions around high growth, improving profitability, and a premium valuation that many investors usually associate with larger global biotechs.

Result: Fair Value of HK$49.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative can quickly break if NEFECON underperforms expectations or if high R&D spending on the broad pipeline strains cash flow and leads to further dilution.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment in this article leaning cautious but curious, it makes sense to check the numbers yourself and decide if the optimism holds up. To see what investors are focusing on, review the 4 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you could miss some of the most compelling setups on the market, so widen your search before making your next move.

• Target potential mispricings by scanning 194 high quality undervalued stocks for stocks that combine quality fundamentals with prices that sit well below their assessed worth.
• Strengthen your income playbook by reviewing 484 dividend fortresses and spotting companies that pair higher yields with more resilient payout records.
• Prioritise resilience by checking 286 resilient stocks with low risk scores to find stocks with lower risk profiles that may better fit a steadier approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com